France· FR:67034579
ENRYLAZE 10 mg/0,5 mL, solution injectable/pour perfusion
A medicinal product containing crisantaspase recombinante, registered in France by JAZZ PHARMACEUTICALS IRELAND LIMITED (IRLANDE).
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- CRISANTASPASE RECOMBINANTE
- Manufacturer
- JAZZ PHARMACEUTICALS IRELAND LIMITED (IRLANDE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009550986833 flacon(s) en verre de 0,5 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Crisantaspase recombinante in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsEnrylaze 10 mg/0,5 ml oplossing voor injectie/infusieJazz Pharmaceuticals Ireland Ltd.
- SpainENRYLAZE 10 MG/0,5 ML, SOLUCION INYECTABLE Y PARA PERFUSIONJazz Pharmaceuticals Ireland Limited
- IrelandEnrylaze 10 mg/0.5 mL solution for injection/infusion.Jazz Pharmaceuticals Ireland Limited
- GermanyErwinasePorton Biopharma Limited
- NorwayErwinasePorton Biopharma Limided
- PolandEnrylazeJazz Pharmaceuticals Ireland Ltd
- BelgiumEnrylaze 10 mg/0.5 mlJazz Pharmaceuticals Ireland
- IcelandEnrylazeJazz Pharmaceuticals Ireland Ltd
Authorised across Europe · EMA
The same active substance is authorised in 11 EEA countries. Names it is sold under:
- Belgium · Erwinase
- Germany · Erwinase
- Denmark · Erwinase
- Spain · Erwinase
- Finland · Erwinase
- United Kingdom (Northern Ireland) · Erwinase
- Ireland · Erwinase
- Netherlands · Erwinase
- Norway · Erwinase
- Portugal · Erwinase
- Sweden · Erwinase
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e4ab93c6-7693-48c9-8c6c-2477681cafa8 GET /v1/drugs/e4ab93c6-7693-48c9-8c6c-2477681cafa8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "67034579",
"date_amm": "2023-09-15",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/23/1747",
"substance": "CRISANTASPASE RECOMBINANTE",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable ou pour perfusion",
"voies_administration": "intramusculaire;intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about crisantaspase recombinante.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.